Unicycive Therapeutics, Inc.
UNCY Nasdaq· Pharmaceutical Preparations
Last close · Oct 26, 2026
$3.58
KIRA · Stoqly’s AI analyst, in plain words
- Unicycive Therapeutics, Inc. lost $26.6M in fiscal 2025.
- Free cash flow was −$31.3M in fiscal 2025, — of revenue.
Market cap
$96.4M
P/E
—
Revenue
—
Net income
−$26.6M
Free cash flow
−$31.3M
Operating margin
—
Unicycive Therapeutics, Inc. in 30 seconds · fiscal 2025
Does it make a profit?
−$26.6M
No. It lost money last year.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Unicycive Therapeutics, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 30, 2026
- Legal name
- Unicycive Therapeutics, Inc.
- CIK
- 0001766140
Unicycive Therapeutics, Inc. · UNCY
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | — | $1.0M | $0.7M | — | — |
| Revenue growth | — | — | −29.0% | — | — |
| Operating margin | — | −1,898.2% | −3,077.6% | — | — |
| Net income | −$10.0M | −$18.1M | −$30.5M | −$36.7M | −$26.6M |
| Net margin | — | −1,898.8% | −4,525.0% | — | — |
| Diluted EPS | −$0.86 | −$1.20 | −$1.28 | −$5.65 | −$1.67 |
| Cash | |||||
| Cash from operations | −$5.8M | −$15.7M | −$18.3M | −$28.6M | −$31.3M |
| Capital expenditure | $0.0M | $0.0M | $0.0M | $0.1M | $0.0M |
| Free cash flow | −$5.8M | −$15.7M | −$18.3M | −$28.6M | −$31.3M |
| FCF margin | — | −1,646.0% | −2,710.4% | — | — |
| Dividends paid | — | — | $0.9M | $1.1M | — |
| Share count change | — | 29.0% | 63.0% | −72.7% | 137.2% |
| Debt and strength | |||||
| Cash and short-term investments | $16.6M | $0.5M | $9.7M | $26.1M | $41.3M |
| Shareholders' equity | $16.5M | −$0.5M | −$3.8M | $7.4M | $30.2M |
| Current ratio | 8.7x | 0.8x | 0.8x | 1.3x | 2.6x |
| Interest coverage | −14.3x | −3,008.7x | −253.3x | −452.4x | −415.7x |
| Returns and quality | |||||
| Return on equity | −145.0% | −225.5% | — | −2,028.1% | −141.1% |
| Return on tangible equity | −60.8% | — | — | −509.0% | −87.9% |
| Piotroski F-score | — | — | 2 | — | — |
| Altman Z'' | 7.4 | −84.0 | −26.8 | −15.5 | −6.8 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Unicycive Therapeutics, Inc. · UNCY
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $3.58 a share, the company is worth $96.4M.
Source: SEC EDGAR XBRL filings (CIK 0001766140). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.